This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:publications:waterhouse_mp_for_lyme_2007 [11.14.2008] – joyful | home:publications:waterhouse_mp_for_lyme_2007 [07.04.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
+ | | ||
+ | |||
+ | |||
+ | **Type:** Article\\ | ||
+ | **Author: | ||
+ | **Publication: | ||
+ | **Citation: | ||
+ | **Related content:** [[https:// | ||
+ | |||
+ | |||
+ | |||
+ | ===== Abstract ===== | ||
+ | |||
+ | A new approach called the Marshall Protocol (MP), is now achieving success in treating chronic Lyme disease. This protocol was originally developed for sarcoidosis by Trevor Marshall PhD, of the Autoimmunity Research Foundation. The MP's main targets are the treatment-resistanct cell wall deficient (CWD, L-form or cyst) forms of //Borrelia burgdorferi// | ||
+ | {{tag> | ||